Giuseppe Pelosi

Summary

Affiliation: Istituto Nazionale Tumori
Country: Italy

Publications

  1. ncbi ΔNp63 (p40) and thyroid transcription factor-1 immunoreactivity on small biopsies or cellblocks for typing non-small cell lung cancer: a novel two-hit, sparing-material approach
    Giuseppe Pelosi
    Department of Pathology and Laboratory Medicine, Fondazione IRCCS National Cancer Institute, Milan, Italy
    J Thorac Oncol 7:281-90. 2012
  2. ncbi Dual role of RASSF1 as a tumor suppressor and an oncogene in neuroendocrine tumors of the lung
    Giuseppe Pelosi
    Division of Pathology and Laboratory MedicineEuropean Institute of Oncology and National Cancer Institute, Milan, Italy
    Anticancer Res 30:4269-81. 2010
  3. ncbi Combined small-cell carcinoma of the lung with quadripartite differentiation of epithelial, neuroendocrine, skeletal muscle, and myofibroblastic type
    Giuseppe Pelosi
    Division of Pathology and Laboratory Medicine, European Institute of Oncology, Milan, Italy
    Virchows Arch 458:497-503. 2011
  4. ncbi Immunhistochemistry by means of widely agreed-upon markers (cytokeratins 5/6 and 7, p63, thyroid transcription factor-1, and vimentin) on small biopsies of non-small cell lung cancer effectively parallels the corresponding profiling and eventual diagnoses
    Giuseppe Pelosi
    Division of Pathology and Laboratory Medicine, European Institute of Oncology, Milan, Italy
    J Thorac Oncol 6:1039-49. 2011
  5. ncbi Methylation-associated down-regulation of RASSF1A and up-regulation of RASSF1C in pancreatic endocrine tumors
    Giorgio Malpeli
    Department of Pathology and Diagnostics, University of Verona, Verona, Italy
    BMC Cancer 11:351. 2011
  6. ncbi Alteration of the E-cadherin/beta-catenin cell adhesion system is common in pulmonary neuroendocrine tumors and is an independent predictor of lymph node metastasis in atypical carcinoids
    Giuseppe Pelosi
    Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan School of Medicine, Milan, Italy
    Cancer 103:1154-64. 2005
  7. ncbi Lung cancer screening with low-dose computed tomography: a non-invasive diagnostic protocol for baseline lung nodules
    Giulia Veronesi
    Department of Thoracic Surgery, European Institute of Oncology, Milan, Italy
    Lung Cancer 61:340-9. 2008
  8. ncbi K-ras gene mutational analysis supports a monoclonal origin of biphasic pleomorphic carcinoma of the lung
    Giuseppe Pelosi
    Department of Pathology and Laboratory Medicine, European Institute of Oncology and University of Milan School of Medicine, Milan, Italy
    Mod Pathol 17:538-46. 2004
  9. ncbi Adjuvant surgery after carboplatin and VP16 in resectable small cell lung cancer
    Giulia Veronesi
    Division of Thoracic Surgery, European Institute of Oncology, Milan, Italy
    J Thorac Oncol 2:131-4. 2007
  10. ncbi A subset of high-grade pulmonary neuroendocrine carcinomas shows up-regulation of matrix metalloproteinase-7 associated with nuclear beta-catenin immunoreactivity, independent of EGFR and HER-2 gene amplification or expression
    Giuseppe Pelosi
    Division of Pathology and Laboratory Medicine, European Institute of Oncology and University of Milan School of Medicine, Milan, Italy
    Virchows Arch 447:969-77. 2005

Detail Information

Publications70

  1. ncbi ΔNp63 (p40) and thyroid transcription factor-1 immunoreactivity on small biopsies or cellblocks for typing non-small cell lung cancer: a novel two-hit, sparing-material approach
    Giuseppe Pelosi
    Department of Pathology and Laboratory Medicine, Fondazione IRCCS National Cancer Institute, Milan, Italy
    J Thorac Oncol 7:281-90. 2012
    ..As sparing material for molecular testing is mandatory, a minimalist immunohistochemistry (IHC)-based diagnostic approach is warranted by means of novel, reliable, and easy-to-assess biomarkers...
  2. ncbi Dual role of RASSF1 as a tumor suppressor and an oncogene in neuroendocrine tumors of the lung
    Giuseppe Pelosi
    Division of Pathology and Laboratory MedicineEuropean Institute of Oncology and National Cancer Institute, Milan, Italy
    Anticancer Res 30:4269-81. 2010
    ..Little is known about the dual role of RAS-association domain family 1 (RASSF1) gene at 3p21.3 in neuroendocrine tumors (NET) of the lung...
  3. ncbi Combined small-cell carcinoma of the lung with quadripartite differentiation of epithelial, neuroendocrine, skeletal muscle, and myofibroblastic type
    Giuseppe Pelosi
    Division of Pathology and Laboratory Medicine, European Institute of Oncology, Milan, Italy
    Virchows Arch 458:497-503. 2011
    ..This tumor had probably derived for clonal evolution of a p53-mutated common ancestor lesion...
  4. ncbi Immunhistochemistry by means of widely agreed-upon markers (cytokeratins 5/6 and 7, p63, thyroid transcription factor-1, and vimentin) on small biopsies of non-small cell lung cancer effectively parallels the corresponding profiling and eventual diagnoses
    Giuseppe Pelosi
    Division of Pathology and Laboratory Medicine, European Institute of Oncology, Milan, Italy
    J Thorac Oncol 6:1039-49. 2011
    ..Little, however, is known about the likelihood of immunohistochemistry (IHC)-assessed small biopsies to effectively parallel profiling and, hence, eventual diagnoses of surgical specimens...
  5. ncbi Methylation-associated down-regulation of RASSF1A and up-regulation of RASSF1C in pancreatic endocrine tumors
    Giorgio Malpeli
    Department of Pathology and Diagnostics, University of Verona, Verona, Italy
    BMC Cancer 11:351. 2011
    ..The RASSF1 locus contains two CpG islands (A and C) and generates seven transcripts (RASSF1A-RASSF1G) by differential promoter usage and alternative splicing...
  6. ncbi Alteration of the E-cadherin/beta-catenin cell adhesion system is common in pulmonary neuroendocrine tumors and is an independent predictor of lymph node metastasis in atypical carcinoids
    Giuseppe Pelosi
    Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan School of Medicine, Milan, Italy
    Cancer 103:1154-64. 2005
    ..To the authors' knowledge, little is known regarding the role of E-cadherin/beta-catenin system dysregulation in pulmonary neuroendocrine tumors...
  7. ncbi Lung cancer screening with low-dose computed tomography: a non-invasive diagnostic protocol for baseline lung nodules
    Giulia Veronesi
    Department of Thoracic Surgery, European Institute of Oncology, Milan, Italy
    Lung Cancer 61:340-9. 2008
    ..We assessed the diagnostic utility of a non-invasive work-up protocol for nodules detected at baseline in volunteers enrolled in our single-centre screening trial, and followed for at least 1 year...
  8. ncbi K-ras gene mutational analysis supports a monoclonal origin of biphasic pleomorphic carcinoma of the lung
    Giuseppe Pelosi
    Department of Pathology and Laboratory Medicine, European Institute of Oncology and University of Milan School of Medicine, Milan, Italy
    Mod Pathol 17:538-46. 2004
    ....
  9. ncbi Adjuvant surgery after carboplatin and VP16 in resectable small cell lung cancer
    Giulia Veronesi
    Division of Thoracic Surgery, European Institute of Oncology, Milan, Italy
    J Thorac Oncol 2:131-4. 2007
    ....
  10. ncbi A subset of high-grade pulmonary neuroendocrine carcinomas shows up-regulation of matrix metalloproteinase-7 associated with nuclear beta-catenin immunoreactivity, independent of EGFR and HER-2 gene amplification or expression
    Giuseppe Pelosi
    Division of Pathology and Laboratory Medicine, European Institute of Oncology and University of Milan School of Medicine, Milan, Italy
    Virchows Arch 447:969-77. 2005
    ..A minor subset of these tumors shows beta-catenin nuclear accumulation in association with increased expression of MMP-7, but not of cyclin D1, independent of EGFR and HER-2 gene amplification or expression...
  11. ncbi 3q26 Amplification and polysomy of chromosome 3 in squamous cell lesions of the lung: a fluorescence in situ hybridization study
    Giuseppe Pelosi
    Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan School of Medicine and Cancer Genetic Unit, IFOM Foundation FIRC Institute of Molecular Oncology Foundation, Milan, Italy
    Clin Cancer Res 13:1995-2004. 2007
    ....
  12. ncbi Imaging of lung hamartomas by multidetector computed tomography and positron emission tomography
    Concetta De Cicco
    Division of Nuclear Medicine, European Institute of Oncology, Milan, Italy
    Ann Thorac Surg 86:1769-72. 2008
    ..Most are discovered on routine x-ray film and require further evaluation. Computed tomography (CT) is insufficient for a benign versus malignant diagnosis in about 30% of cases...
  13. ncbi Lack of prognostic implications of HER-2/neu abnormalities in 345 stage I non-small cell carcinomas (NSCLC) and 207 stage I-III neuroendocrine tumours (NET) of the lung
    Giuseppe Pelosi
    Division of Pathology and Laboratory Medicine, European Institute of Oncology and University of Milan School of Medicine, Milan, Italy
    Int J Cancer 113:101-8. 2005
    ..Among neuroendocrine tumours, LCNEC show a slightly higher prevalence of either HER-2/neu gene amplification or protein overexpression...
  14. ncbi Randomized biomarker trial of anastrozole or low-dose tamoxifen or their combination in subjects with breast intraepithelial neoplasia
    Bernardo Bonanni
    Divisions of Cancer Prevention and Genetics, European Institute of Oncology, Milan, University of Milan School of Medicine, Milan, Italy
    Clin Cancer Res 15:7053-60. 2009
    ..The influence of CYP2D6 genotype on tamoxifen effects was also determined...
  15. ncbi Extended pneumonectomy with partial resection of the left atrium, without cardiopulmonary bypass, for lung cancer
    Lorenzo Spaggiari
    Department of Thoracic Surgery European Institute of Oncology, Milan, Italy
    Ann Thorac Surg 79:234-40. 2005
    ..The present study analyzed a single center's experience with this extended surgery, highlighting the surgery's technical aspects, postoperative outcomes, and oncologic results...
  16. ncbi Screening-detected lung cancers: is systematic nodal dissection always essential?
    Giulia Veronesi
    Division of Thoracic Surgery, European Institute of Oncology, Milan, Italy
    J Thorac Oncol 6:525-30. 2011
    ..To address whether systematic lymph node dissection is always necessary in early lung cancer, we identified factors predicting nodal involvement in a screening series and applied them to nonscreening-detected cancers...
  17. ncbi CD117 immunoreactivity in high-grade neuroendocrine tumors of the lung: a comparative study of 39 large-cell neuroendocrine carcinomas and 27 surgically resected small-cell carcinomas
    Giuseppe Pelosi
    Division of Pathology and Laboratory Medicine, European Institute of Oncology, Via G Ripamonti 435, 20141 Milan, Italy
    Virchows Arch 445:449-55. 2004
    ..There was no association between CD117 immunoreactivity and survival in either small-cell carcinoma or large-cell neuroendocrine carcinoma patients...
  18. ncbi CD117 immunoreactivity in stage I adenocarcinoma and squamous cell carcinoma of the lung: relevance to prognosis in a subset of adenocarcinoma patients
    Giuseppe Pelosi
    Department of Pathology and Laboratory Medicine, European Institute of Oncology and University of Milan School of Medicine, Milan, Italy
    Mod Pathol 17:711-21. 2004
    ..Targeting the CD117 pathway could be a novel therapeutic strategy in a subset of pulmonary carcinomas...
  19. ncbi Lung cancer risk prediction to select smokers for screening CT--a model based on the Italian COSMOS trial
    Patrick Maisonneuve
    Division of Epidemiology and Biostatistics, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Cancer Prev Res (Phila) 4:1778-89. 2011
    ..The Bach model incorporating CT findings at baseline screening could help defining the time interval to subsequent screening in individual participants. Further studies are necessary to validate these models...
  20. ncbi Prognostic role of lymph node involvement in lung metastasectomy
    Giulia Veronesi
    Division of Thoracic Surgery, European Institute of Oncology, Milan, Italy
    J Thorac Cardiovasc Surg 133:967-72. 2007
    ..We assessed the prognostic value of lymph node status in lung metastasectomy and the prevalence of unexpected mediastinal lymph node involvement after lymph node sampling or dissection...
  21. ncbi Pathologic and molecular features of screening low-dose computed tomography (LDCT)-detected lung cancer: a baseline and 2-year repeat study
    Giuseppe Pelosi
    Division of Pathology and Laboratory Medicine, European Institute of Oncology, Milan, Italy
    Lung Cancer 62:202-14. 2008
    ..Repeat cancers are potentially aggressive tumors. K-ras mutation analysis supports the impression that multifocal tumors at baseline are separate synchronous primaries...
  22. ncbi Detecting cell-free circulating hTERT mRNA in the plasma may identify a subset of nonsmall cell lung cancer patients
    Giuseppe Pelosi
    Division of Pathology and Laboratory Medicine, European Institute of Oncology and University of Milan School of Medicine, Milan, Italy
    Virchows Arch 448:7-15. 2006
    ..It can be added to the panel of multiple genetic tracers to detect lung cancer in the plasma of patients, although, per se, it is not specific for this tumor...
  23. ncbi A critical appraisal of the adjuvant chemotherapy guidelines for patients with completely resected T3N0 non-small-cell lung cancer
    Tommaso De Pas
    New Drugs Development and Clinical Pharmacology Unit, Department of Medicine, European Institute of Oncology, Milan, Italy
    Acta Oncol 49:480-4. 2010
    ..However, these two tumor subgroups should be considered as different entities. While the efficacy of adjuvant chemotherapy has been established in patients with T1-2N1 NSCLC, its benefit in patients with T3N0 tumor remains questionable...
  24. ncbi Review article: pulmonary sarcomatoid carcinomas: a practical overview
    Giuseppe Pelosi
    Division of Pathology and Laboratory Medicine, University of Milan School of Medicine, Milan
    Int J Surg Pathol 18:103-20. 2010
    ..Conceivably, targeting the epithelial-mesenchymal transition program could become a valid therapeutic strategy for these life-threatening tumors, whose sensitivity to current medical manipulation is disappointing...
  25. ncbi Randomized dose-ranging trial of tamoxifen at low doses in hormone replacement therapy users
    Andrea Decensi
    Division of Chemoprevention, European Institute of Oncology, Milan, Italy
    J Clin Oncol 25:4201-9. 2007
    ..We assessed the optimal biologic dose and schedule of tamoxifen in HRT users using surrogate end point biomarkers and menopausal symptoms...
  26. ncbi p63 immunoreactivity in lung cancer: yet another player in the development of squamous cell carcinomas?
    Giuseppe Pelosi
    Department of Pathology and Laboratory Medicine, European Institute of Oncology and University of Milan School of Medicine, Milan, Italy
    J Pathol 198:100-9. 2002
    ..Although p63 is likely to be involved in the development of pulmonary squamous cell carcinoma, it does not carry any prognostic implication for NSCLC patients...
  27. ncbi Prognostic implications of neuroendocrine differentiation and hormone production in patients with Stage I nonsmall cell lung carcinoma
    Giuseppe Pelosi
    Division of Pathology and Laboratory Medicine, European Institute of Oncology and University of Milan School of Medicine, Milan, Italy
    Cancer 97:2487-97. 2003
    ..However, little is known regarding the prevalence and clinical implications of NE differentiation in patients with Stage I NSCLC...
  28. ncbi Detecting lung cancer in plasma with the use of multiple genetic markers
    Francesca Andriani
    Department of Experimental Oncology, Istituto Nazionale Tumori, Milan, Italy
    Int J Cancer 108:91-6. 2004
    ..2%) of stage I patients whose tumors had an alteration. These results provide the proof of principle that plasma DNA alterations are tumor-specific in most cases and support blood testing as a noninvasive strategy for early detection...
  29. ncbi Tumour CEA as predictor of better outcome in squamous cell carcinoma of the lung
    Giulia Veronesi
    Thoracic Surgery Division, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Lung Cancer 48:233-40. 2005
    ..In SCC patients, the magnitude of the hazard ratio was confirmed even if the precision of the estimate is decreased (p=0.06). In conclusion, T-CEA expression appears to be an important prognostic factor in early stage SSC of the lung...
  30. ncbi Difficulties encountered managing nodules detected during a computed tomography lung cancer screening program
    Giulia Veronesi
    Department of Thoracic Surgery, European Institute of Oncology, Milan, Italy
    J Thorac Cardiovasc Surg 136:611-7. 2008
    ..We evaluated the pitfalls, difficulties, and sources of mistakes in the management of lung nodules detected in volunteers in the Cosmos single-center screening trial...
  31. ncbi Genetic alterations in combined neuroendocrine neoplasms of the lung
    Tiziana D'Adda
    Department of Pathology and Laboratory Medicine, Section of Pathological Anatomy, University of Parma, Parma, Italy
    Mod Pathol 21:414-22. 2008
    ..The genetic differences observed provide the basis for the divergent differentiation and parallel the morphological differences in the two components of these combined neuroendocrine neoplasms...
  32. ncbi Alterations of the Notch pathway in lung cancer
    Britta Westhoff
    IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Milan, Italy
    Proc Natl Acad Sci U S A 106:22293-8. 2009
    ..Our results show that the deregulation of the Notch pathway is a relatively frequent event in NSCLCs and suggest that it might represent a possible target for molecular therapies in these tumors...
  33. ncbi Results of chest wall resection for recurrent or locally advanced breast malignancies
    Giulia Veronesi
    Division of Thoracic Surgery, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Breast 16:297-302. 2007
    ....
  34. ncbi Independent value of fascin immunoreactivity for predicting lymph node metastases in typical and atypical pulmonary carcinoids
    Giuseppe Pelosi
    Department of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan School of Medicine, Via G Ripamonti, 435, I 20141 Milan, Italy
    Lung Cancer 42:203-13. 2003
    ..Targeting the fascin pathway could be a novel therapeutic strategy of pulmonary carcinoids...
  35. ncbi A modified vimentin histological score helps recognize pulmonary sarcomatoid carcinoma in small biopsy samples
    Giuseppe Pelosi
    Department of Pathology and Laboratory Medicine, Fondazione IRCCS National Cancer Institute, Milan, Italy
    Anticancer Res 32:1463-73. 2012
    ..As pulmonary sarcomatoid carcinomas (PSCs) are life-threatening tumors, an improvement in their recognition in small-sized tumor samples is clinically warranted...
  36. ncbi Pleomorphic carcinomas of the lung show a selective distribution of gene products involved in cell differentiation, cell cycle control, tumor growth, and tumor cell motility: a clinicopathologic and immunohistochemical study of 31 cases
    Giuseppe Pelosi
    Department of Pathology and Laboratory Medicine, Institute of European Oncology and University of Milan School of Medicine, Italy
    Am J Surg Pathol 27:1203-15. 2003
    ....
  37. ncbi Subclavicular recurrence of breast cancer: does surgery play a role?
    Giulia Veronesi
    Division of Thoracic Surgery, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Breast 15:649-53. 2006
    ..We conclude that the technique may be useful, in selected cases, for palliation only...
  38. ncbi Computer-assisted image analysis of breast fine needle aspiration in a randomized chemoprevention trial of fenretinide vs. placebo in HRT users
    Davide Serrano
    Division of Chemoprevention, European Institute of Oncology, Milan, Italy
    Breast 17:91-7. 2008
    ..Digital nuclear morphometric analysis can capture subtle differences along neoplastic progression. Studies showed different profiles from normal to cancer lesions. Our goal is to utilize this method as biomarker in chemoprevention trials...
  39. ncbi Primary thoracic synovial sarcoma: factors affecting long-term survival
    Domenico Galetta
    Division of Thoracic Surgery, European Institute of Oncology, Milan, Italy
    J Thorac Cardiovasc Surg 134:808-9. 2007
  40. ncbi Multiparametric molecular characterization of pulmonary sarcomatoid carcinoma reveals a nonrandom amplification of anaplastic lymphoma kinase (ALK) gene
    Giuseppe Pelosi
    Department of Pathology and Laboratory Medicine, Fondazione IRCCS National Cancer Institute, Milan, Italy
    Lung Cancer 77:507-14. 2012
    ..Genetic alterations for targeting therapy are largely unexplored issues in pulmonary sarcomatoid carcinoma (PSC), a life-threatening tumor subset...
  41. ncbi Malignancy-associated X chromosome allelic losses in foregut endocrine neoplasms: further evidence from lung tumors
    Lorena Bottarelli
    Department of Pathology and Laboratory Medicine, Section of Pathological Anatomy, University of Parma, Parma, Italy
    Mod Pathol 18:795-805. 2005
    ....
  42. ncbi A primary pure yolk sac tumor of the lung exhibiting CDX-2 immunoreactivity and increased serum levels of alkaline phosphatase intestinal isoenzyme
    Giuseppe Pelosi
    Division of Pathology, European Institute of Oncology and University of Milan School of Medicine, Milan, Italy
    Int J Surg Pathol 14:247-51. 2006
    ..The pathologist should be aware of yolk sac tumor arising in the lung and that alkaline phosphatase intestinal isoform could become an additional serum marker for such a tumor...
  43. ncbi Structural lung damage after chemotherapy fact or fiction?
    Francesco Leo
    Division of Thoracic Surgery, European Institute of Oncology, Via Ripamonti 435, 20100 Milan, Italy
    Lung Cancer 67:306-10. 2010
    ..The hypothesis of the study is that patients who received preoperative chemotherapy may have subclinical parenchymal damage, increasing their risk of respiratory complications...
  44. ncbi Randomized phase II trial of inhaled budesonide versus placebo in high-risk individuals with CT screen-detected lung nodules
    Giulia Veronesi
    Division of Thoracic Surgery, European Institute of Oncology, Via Ripamonti 435, I 20141 Milan, Italy
    Cancer Prev Res (Phila) 4:34-42. 2011
    ..There was a trend toward regression of nonsolid and partially solid nodules after budesonide treatment. Because a subset of these nodules is more likely to represent precursors of adenocarcinoma, additional follow-up is needed...
  45. ncbi Modulation of epidermal growth factor receptor status by chemotherapy in patients with locally advanced non-small-cell lung cancer is rare
    Tommaso De Pas
    Division of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    J Clin Oncol 22:4966-70. 2004
    ....
  46. ncbi Optimizing pemetrexed-gemcitabine combination in patients with advanced non-small cell lung cancer: a pharmacogenetic approach
    Tommaso M De Pas
    Unit of Medical Oncology of Respiratory Tract and Sarcomas, New Drugs Development Division, European Institute of Oncology, Milan, Italy
    J Thorac Oncol 6:768-73. 2011
    ..A pharmacogenetic approach was adopted to evaluate hENT1 and dCK expressions in humans and to identify the potential best time interval to administer gemcitabine after pemetrexed in patients with advanced NSCLC...
  47. ncbi Superior vena cava replacement for lung cancer using a heterologous (bovine) prosthesis: preliminary results
    Lorenzo Spaggiari
    Department of Thoracic Surgery, European Institute of Oncology, Milan, Italy
    J Thorac Cardiovasc Surg 131:490-1. 2006
  48. ncbi Salivary gland-type tumors with myoepithelial differentiation arising in pulmonary hamartoma: report of 2 cases of a hitherto unrecognized association
    Giuseppe Pelosi
    Division of Pathology and Laboratory Medicine, European Institute of Oncology and University of Milan School of Medicine, Milan, Italy
    Am J Surg Pathol 30:375-87. 2006
    ....
  49. ncbi Role of positron emission tomography scanning in the management of lung nodules detected at baseline computed tomography screening
    Giulia Veronesi
    Department of Thoracic Surgery, European Institute of Oncology, Milan, Italy
    Ann Thorac Surg 84:959-65; discussion 965-6. 2007
    ..We present results using positron tomography scanning (CT-PET) to evaluate LD-CT-detected lung nodules during the first year of the Continuing Observation of Smoking Subjects (COSMOS) early detection trial for lung cancer...
  50. ncbi Brief report: activity of imatinib in a patient with platelet-derived-growth-factor receptor positive malignant solitary fibrous tumor of the pleura
    Tommaso De Pas
    New Drugs Development Unit, European Institute of Oncology, Milan, Italy
    J Thorac Oncol 3:938-41. 2008
    ..Treatment with imatinib should be considered for patients with recurrent or unresectable MSFTs with PDGFR expression...
  51. ncbi Decreased immunoreactivity of CD99 is an independent predictor of regional lymph node metastases in pulmonary carcinoid tumors
    Giuseppe Pelosi
    Division of Pathology and Laboratory Medicine, European Institute of Oncology, Milan, Italy
    J Thorac Oncol 1:468-77. 2006
    ..Few data are available on the prevalence and clinicopathological meaning of CD99, the transmembrane product of the pseudoautosomal MIC2 gene, in pulmonary neuroendocrine tumors...
  52. ncbi Video-assisted management of malignant pleural effusion in breast carcinoma
    Roberto Gasparri
    Division of Thoracic Surgery, European Institute of Oncology, Milan, Italy
    Cancer 106:271-6. 2006
    ..Concomitant biopsies performed during the VATS procedure were a determining factor in the subsequent decision-making process...
  53. ncbi Immunoreactivity for sex steroid hormone receptors in pulmonary hamartomas
    Giuseppe Pelosi
    Division of Pathology and Laboratory Medicine, European Institute of Oncology and University of Milan School of Medicine, Voa G Ripamonti 435, I 20141 Milan, Italy
    Am J Surg Pathol 30:819-27. 2006
    ..In conclusion, sex steroid hormone receptor expression is a nonrandom event in pulmonary hamartoma, and may be related to the development and growth of this tumor...
  54. ncbi Treatment of pulmonary metastases from primary intraosseous odontogenic carcinoma
    Domenico Galetta
    Division of Thoracic Surgery, European Institute of Oncology, Milan, Italy
    Lancet Oncol 7:272-3. 2006
  55. ncbi Early lung-cancer detection with spiral CT and positron emission tomography in heavy smokers: 2-year results
    Ugo Pastorino
    Division of Thoracic Surgery, Istituto Nazionale Tumori, Milan, Italy
    Lancet 362:593-7. 2003
    ..We investigated the efficacy of repeated yearly spiral CT and selective use of positron emission tomography (PET) in a large cohort of high-risk volunteers...
  56. ncbi Large cell neuroendocrine carcinoma of the lung: a retrospective analysis of 144 surgical cases
    Giulia Veronesi
    Division of Thoracic Surgery, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Lung Cancer 53:111-5. 2006
    ..We retrospectively evaluated outcomes in a series of patients with a pathological diagnosis of large cell neuroendocrine lung carcinoma, who underwent lung resection. We also assessed the utility of chemotherapy in a small subgroup...
  57. ncbi Images in pathology: micronodular epithelial hyperplasia in ectopic thymus
    Giuseppe Pelosi
    Division of Pathology and Laboratory Medicine, European Institute of Oncology and University of Milan School of Medicine, Milan, Italy
    Int J Surg Pathol 14:73-4. 2006
  58. ncbi Effects of raloxifene on sex steroid hormones and C-telopeptide in postmenopausal women with primary breast cancer
    Harriet Johansson
    Division of Chemoprevention, European Institute of Oncology, Milan, Italy
    Breast Cancer Res Treat 98:167-72. 2006
    ..024) and E2 (p=0.01), and positively with DHEA-S (p=0.016) and CTX (p=0.040). Our results provide evidence for an early endocrine effect of raloxifene which further suggests a favorable impact on breast cancer prevention...
  59. ncbi Pulmonary resections: cytostructural effects of different-wavelength lasers versus electrocautery
    Paolo Scanagatta
    Fondazione IRCCS National Cancer Institute, Milan, Italy
    Tumori 98:90-3. 2012
    ..The aim of the present study was to evaluate the parenchymal damage caused by different surgical instruments: a new generation electrosurgical scalpel and two different-wavelength lasers...
  60. ncbi Images in pathology. Benign hyperplastic mesothelial cells in lymph node
    Giuseppe Pelosi
    Division of Pathology and Laboratory Medicine, European Institute of Oncology and University of Milan School of Medicine, Milan, Italy
    Int J Surg Pathol 15:297-9. 2007
  61. ncbi Invited commentary
    Giuseppe Pelosi
    , Via G. Ripamonti, 435, Milan, Italy
    Ann Thorac Surg 86:1090-1. 2008
  62. ncbi Typical and atypical pulmonary carcinoid tumor overdiagnosed as small-cell carcinoma on biopsy specimens: a major pitfall in the management of lung cancer patients
    Giuseppe Pelosi
    Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan School of Medicine, Milan, Italy
    Am J Surg Pathol 29:179-87. 2005
    ....
  63. ncbi Preliminary results on safety and activity of a randomized, double-blind, 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in premenopausal women
    Aliana Guerrieri-Gonzaga
    Division of Chemoprevention, European Institute of Oncology, Milan, Italy
    J Clin Oncol 24:129-35. 2006
    ..CONCLUSION: The combination of low-dose tamoxifen and fenretinide is safe but not synergistic in lowering IGF-I levels in premenopausal women. The clinical implications require further follow-up...
  64. ncbi Mediastinal-like growing teratoma syndrome
    Giulia Veronesi
    Division of Thoracic Surgery, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    J Thorac Cardiovasc Surg 130:228-9. 2005
  65. ncbi The classification of lung carcinoma: time to change the morphology-based approach?
    Giuseppe Pelosi
    Divisione di Anatomia Patologica e Medicina di Laboratorio, European Institute of Oncology, Milan, Italy
    Int J Surg Pathol 18:161-72. 2010
    ....
  66. ncbi A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer
    Fabrizio Bianchi
    IFOM, the FIRC Institute for Molecular Oncology Foundation, at the IFOM IEO Campus, Milan, Italy
    EMBO Mol Med 3:495-503. 2011
    ..Thus, our test displays a number of features of clinical relevance that project its utility in programs for the early detection of NSCLC...
  67. ncbi Intravascular papillary endothelial hyperplasia of the renal vein
    Giuseppe Pelosi
    Division of Pathology and Laboratory Medicine, European Institute of Oncology and University of Milan School of Medicine, Milan, Italy
    Int J Surg Pathol 19:518-20. 2011
    ....
  68. ncbi Quantification of free circulating DNA as a diagnostic marker in lung cancer
    Gabriella Sozzi
    Department of Experimental Oncology, Istituto Nazionale Tumori, Milan, Italy
    J Clin Oncol 21:3902-8. 2003
    ..Levels of plasma DNA could also identify higher-risk individuals for lung cancer screening and chemoprevention trials...
  69. ncbi Two-year survival after multiple bilateral lung metastasectomies for cranial meningioma
    Giulia Veronesi
    Division of Thoracic Surgery, European Institute of Oncology, Milan, Italy
    Ann Thorac Surg 80:1129-30. 2005
    ..We present a case of extensive bilateral lung metastases due to recurrent cranial meningioma, which was successfully treated by aggressive, staged metastasectomies...
  70. ncbi Erlotinib-induced breast cancer regression
    Chiara Catania
    Medical Care Unit, Department of Medicine, European Institute of Oncology, Milan, Italy
    Ann Pharmacother 40:2043-7. 2006
    ..To report a case of erlotinib-induced breast cancer regression...